MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

Jacobs, 1992, Report of the conference on low blood cholesterol:mortality associations, Circulation, 86, 1046, 10.1161/01.CIR.86.3.1046

Stamler, 1993, Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial, Diabetes Care, 16, 434, 10.2337/diacare.16.2.434

Chen, 1990

Chen, 1991, Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations, BMJ, 303, 276, 10.1136/bmj.303.6797.276

Szatrowski, 1984, Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort, J Chron Dis, 7, 569, 10.1016/0021-9681(84)90007-9

1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S), Lancet, 344, 1383

Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001

Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401

1997, The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts, N Engl J Med, 336, 153, 10.1056/NEJM199701163360301

1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902

Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615

Armitage, 2000, Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials, Heart, 84, 357, 10.1136/heart.84.4.357

Bandyopadhyay, 2001, Age and gender bias in statin trials, Q J Med, 94, 127, 10.1093/qjmed/94.3.127

Waters, 2001, Low-density-lipoprotein cholesterol goals for patients with coronary disease: treating between the lines, Circulation, 104, 2635, 10.1161/circ.104.22.2635

2001, Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries, Lancet, 357, 995, 10.1016/S0140-6736(00)04235-5

Muldoon, 1990, Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials, BMJ, 301, 309, 10.1136/bmj.301.6747.309

Oliver, 1991, Might treatment of hypercholesterolaemia increase noncardiac mortality?, Lancet, 1, 1529, 10.1016/0140-6736(91)93208-Q

Davey Smith, 1992, Should there be a moratorium on the use of cholesterol lowering drugs?, BMJ, 304, 431, 10.1136/bmj.304.6824.431

Newman, 1996, Carcinogenicity of lipid-lowering drugs, JAMA, 275, 55, 10.1001/jama.1996.03530250059028

Muldoon, 2001, Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials, BMJ, 322, 11, 10.1136/bmj.322.7277.11

Weverling-Rijnsburger, 1997, Total cholesterol and risk of mortality in the oldest old, Lancet, 350, 1119, 10.1016/S0140-6736(97)04430-9

Schatz, 2001, Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study, Lancet, 358, 351, 10.1016/S0140-6736(01)05553-2

1999, MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience, Eur Heart J, 20, 725, 10.1053/euhj.1998.1350

2002, MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 23, 10.1016/S0140-6736(02)09328-5

Prior, 1993, C-peptide and the classification of diabetes mellitus patients in the early treatment diabetic retinopathy study: report number 6, Ann Epidemiol, 3, 9, 10.1016/1047-2797(93)90004-N

Lang, 1991, Estimating the effect of the run-in on the power of the Physicians' Health Study, Stat Med, 10, 1585, 10.1002/sim.4780101010

Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 6, 499, 10.1093/clinchem/18.6.499

McNamara, 1995, Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated, Clin Chem, 41, 232, 10.1093/clinchem/41.2.232

Jialal, 1995, Comparison of an immunoprecipitation method for direct measurement of LDL cholesterol with beta-quantification (ultracentrifugation), Am J Clin Pathol, 104, 76, 10.1093/ajcp/104.1.76

White, 1978, Allocation of patients to treatment groups in a controlled clinical study, Br J Cancer, 37, 849, 10.1038/bjc.1978.124

Peto, 1977, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples, Br J Cancer, 35, 1, 10.1038/bjc.1977.1

Collins, 2001, Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials, Lancet, 357, 373, 10.1016/S0140-6736(00)03651-5

Collins, 1992, Cholesterol and total mortality: need for larger trials, BMJ, 304, 1689, 10.1136/bmj.304.6843.1689

1995, Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens, Am J Cardiol, 75, 1130, 10.1016/S0002-9149(99)80744-9

Brown, 2001, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N Engl J Med, 345, 1583, 10.1056/NEJMoa011090

1998, Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS), Circulation, 97, 1440, 10.1161/01.CIR.97.15.1440

Sacks, 1998, Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial, Circulation, 97, 1446, 10.1161/01.CIR.97.15.1446

Pedersen, 1998, Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S), Circulation, 97, 1453, 10.1161/01.CIR.97.15.1453

Kivipelto, 2001, Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study, BMJ, 322, 1447, 10.1136/bmj.322.7300.1447

Jick, 2000, Statins and the risk of dementia, Lancet, 356, 1627, 10.1016/S0140-6736(00)03155-X

Rockwood, 2002, Use of lipid-lowering agents, indication bias, and the risk of dementia in communitydwelling elderly people, Arch Neurol, 59, 223, 10.1001/archneur.59.2.223

Prince, 1999, The development and initial validation of a telephone-administered cognitive test battery (TACT), Int J Methods Psych Res, 8, 49, 10.1002/mpr.56

Chan, 2000, Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women, Lancet, 355, 2185, 10.1016/S0140-6736(00)02400-4

Pasco, 2002, Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study, Arch Intern Med, 162, 537, 10.1001/archinte.162.5.537

Reid, 2001, Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial, Lancet, 357, 509, 10.1016/S0140-6736(00)04042-3

Byington, 2001, Reduction of stroke events with pravastat in the Prospective Pravastatin Pooling (PPP) Project, Circulation, 103, 387, 10.1161/01.CIR.103.3.387

Sandercock, 2001, Statins for stroke prevention?, Lancet, 357, 1548, 10.1016/S0140-6736(00)04779-6

Sacks, 2000, Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project, Circulation, 102, 1893, 10.1161/01.CIR.102.16.1893

Staffa, 2002, Cerivastatin and reports of fatal rhabdomylosis, N Engl J Med, 346, 539, 10.1056/NEJM200202143460721

2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486

Wood, 1998, Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention, Eur Heart J, 19, 1434, 10.1053/euhj.1998.1243

Thorvaldsen, 1995, Stroke incidence, case fatality, and mortality in the WHO MONICA Project, Stroke, 26, 361, 10.1161/01.STR.26.3.361

2002, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324, 71, 10.1136/bmj.324.7329.71

Yusuf, 1985, Beta blockade during and after myocardial infarction: an overview of the randomized trials, Prog Card Dis, 27, 335, 10.1016/S0033-0620(85)80003-7

2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301

2000, Effects of ACE inhibitors, calcium antagonists, and other blood-pressurelowering drugs: results of prospectively designed overviews of randomised trials, Lancet, 356, 1955, 10.1016/S0140-6736(00)03307-9